Suspicious of Acute Kidney Graft Rejection: Tacrolimus Pharmacokinetics Under Methylprednisolone Therapy
- PMID: 37861009
- DOI: 10.2174/0125899775266172231004074317
Suspicious of Acute Kidney Graft Rejection: Tacrolimus Pharmacokinetics Under Methylprednisolone Therapy
Abstract
Background: Acute rejection remains one of the main complications in the first months after transplantation and may influence long-term outcomes. Tacrolimus has proven its usefulness in solid organ transplants and its monitoring through the application of pharmacokinetic concepts to optimize individual drug therapy.
Objective: This research proposes to evaluate the tacrolimus pharmacokinetic parameters in patients suspected of acute kidney graft rejection under methylprednisolone pulse therapy.
Methods: Eleven adult tacrolimus-treated renal recipients were selected from a prospective, single-arm, single-center cohort study, with suspicion of acute rejection although in use of methylprednisolone pulses therapy. They were followed up for three months posttransplantation, being tacrolimus trough serum concentrations determined using a chemiluminescent magnetic immunoassay, and pharmacokinetic parameters were estimated by using a nonlinear mixed-effects model implemented by Monolix 2020R1. A tacrolimus trough serum concentration range of 8 to 12 ng.mL-1 was considered therapeutic.
Results: Six patients showed acute cellular rejection, and two of them in addition had an antibody- mediated rejection. Tacrolimus trough serum concentration was below the reference range in eight patients. Most patients showed a high tacrolimus concentration intrapatient and pharmacokinetic parameters variability.
Conclusion: The obtained pharmacokinetics parameters helped in understanding the kidney recipient patients' tacrolimus behavior, assisting in the improvement of individual drug therapy and reducing the risk of acute rejection episodes.
Keywords: Tacrolimus; acute rejection; immunosuppression therapy.; kidney transplantation; pharmacokinetics parameters; therapeutic drug monitoring.
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
Similar articles
-
Time to reach tacrolimus maximum blood concentration,mean residence time, and acute renal allograft rejection: an open-label, prospective, pharmacokinetic study in adult recipients.Clin Ther. 2004 Nov;26(11):1834-44. doi: 10.1016/j.clinthera.2004.11.004. Clin Ther. 2004. PMID: 15639695 Clinical Trial.
-
Clinical Implication of Mycophenolic Acid Trough Concentration Monitoring in Kidney Transplant Patients on a Tacrolimus Triple Maintenance Regimen: A Single-Center Experience.Ann Transplant. 2017 Nov 28;22:707-718. doi: 10.12659/aot.906041. Ann Transplant. 2017. PMID: 29180612 Free PMC article.
-
Population pharmacokinetic modelling and design of a Bayesian estimator for therapeutic drug monitoring of tacrolimus in lung transplantation.Clin Pharmacokinet. 2012 Mar 1;51(3):175-86. doi: 10.2165/11594760-000000000-00000. Clin Pharmacokinet. 2012. PMID: 22339449
-
Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation.Clin Pharmacokinet. 2004;43(10):623-53. doi: 10.2165/00003088-200443100-00001. Clin Pharmacokinet. 2004. PMID: 15244495 Review.
-
Tacrolimus: a further update of its use in the management of organ transplantation.Drugs. 2003;63(12):1247-97. doi: 10.2165/00003495-200363120-00006. Drugs. 2003. PMID: 12790696 Review.
References
-
- Mohammadpour N.; Elyasi S.; Vahdati N.; Mohammadpour A.H.; Shamsara J.; A review on therapeutic drug monitoring of immunosuppressant drugs. Iran J Basic Med Sci 2011,14(6),485-498 - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical